Cullinan Associates’s AstraZeneca AZN Stock Holding History

Cullinan Associates’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$761K	Hold	4,013	–	–	0.06%	135
2026 Q1	$791K	Hold	4,013	–	–	0.06%	130
2025 Q4	$738K	Hold	4,013	–	–	0.05%	145
2025 Q3	$616K	Hold	4,013	–	–	0.04%	154
2025 Q2	$561K	Sell	4,013 -2,500	-38%	-$350K	0.04%	164
2025 Q1	$957K	Hold	6,513	–	–	0.07%	128
2024 Q4	$853K	Hold	6,513	–	–	0.05%	139
2024 Q3	$1.01M	Hold	6,513	–	–	0.06%	138
2024 Q2	$1.02M	Hold	6,513	–	–	0.06%	142
2024 Q1	$883K	Buy	6,513 +749	+13%	+$99.2K	0.05%	159
2023 Q4	$776K	Sell	5,764 -1	-0%	-$130	0.04%	163
2023 Q3	$781K	Sell	5,765 -1	-0%	-$137	0.05%	155
2023 Q2	$825K	Buy	5,766 +180	+3%	+$26.5K	0.05%	170
2023 Q1	$775K	Sell	5,586 -18	-0.3%	-$2.42K	0.05%	170
2022 Q4	$760K	Buy	5,604 +3,063	+121%	+$384K	0.04%	177
2022 Q3	$279K	Sell	2,541 -15,291	-86%	-$1.94M	0.02%	210
2022 Q2	$2.36M	Sell	17,832 -439	-2%	-$57.6K	0.14%	115
2022 Q1	$2.42M	Sell	18,271 -509	-3%	-$61K	0.13%	117
2021 Q4	$2.19M	Sell	18,780 -1,067	-5%	-$126K	0.11%	120
2021 Q3	$2.38M	Buy	+19,847	New	+$2.31M	0.13%	115

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Cullinan Associates's AZN Position: Q2 2026 in Review

Cullinan Associates held its AstraZeneca (AZN) position steady in Q2 2026 at 4,013 shares worth $761K. The position accounts for 0.06% of the portfolio, ranked #135.

Cullinan Associates first reported a position in AZN in Q3 2021 and has held it in 20 quarters since. The position peaked at $2.42M in Q1 2022. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Cullinan Associates held 4,013 shares of AstraZeneca worth $761K as of Q2 2026.
Cullinan Associates left its AstraZeneca share count unchanged in Q2 2026.
AstraZeneca made up 0.06% of Cullinan Associates's portfolio in Q2 2026, its #135 holding.
Cullinan Associates first reported a position in AstraZeneca in Q3 2021 and has held it in 20 quarters since.
Cullinan Associates's AstraZeneca position peaked at $2.42M in Q1 2022.
1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Cullinan Associates's 13F filing for Q2 2026, filed 29 Jul 2026.